<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02201342</url>
  </required_header>
  <id_info>
    <org_study_id>PHN-Udenafil-01</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <nct_id>NCT02201342</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents</brief_title>
  <official_title>A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mezzion Pharma Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Heart Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mezzion Pharma Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan&#xD;
      physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic&#xD;
      measures of exercise capacity, ventricular performance, and vascular function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose escalation trial to determine the pharmacokinetics, safety and tolerance of udenafil&#xD;
      in male and female adolescent subjects with single ventricle physiology that that have&#xD;
      undergone the Fontan surgical procedure. Pharmacodynamic data will also be collected to&#xD;
      evaluate the effect of udenafil on acute exercise performance, peripheral vascular function&#xD;
      and indices of myocardial performance. Five udenafil cohorts will be evaluated in additional&#xD;
      to one drug free cohort&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with Serious Adverse Events</measure>
    <time_frame>5 days</time_frame>
    <description>Safety will be measured by the number of subjects experience serious adverse events possibly or probably related to study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance of parent drug and active metabolite</measure>
    <time_frame>Day 5, Zero to 48 hours post last dose</time_frame>
    <description>Plasma clearance of parent drug and active metabolite will be determine after the administration of the last dose on day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of maximum oxygen consumption (VO2)</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Change in maximum oxygen consumption after standard exercise testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAT Index</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Measurement of the PAT reactive hyperemia index by the EndoPAT device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Performance Index (MPI)</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Myocardial Performance Index determined by echocardiogram.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Single Ventricle Heart Disease After Fontan Surgery</condition>
  <arm_group>
    <arm_group_label>Udenafil Dose Level 1 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil tablet dose Level 1 daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil Dose Level 1 bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil Dose Level 1 twice daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil Dose Level 2 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil tablet dose level 2 once daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil Dose Level 2 bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil tablet dose level 2 twice daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Udenafil Dose Level 3 qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil tablet dose level 3 daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Drug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>Drug</description>
    <arm_group_label>Udenafil Dose Level 1 bid</arm_group_label>
    <arm_group_label>Udenafil Dose Level 1 qd</arm_group_label>
    <arm_group_label>Udenafil Dose Level 2 bid</arm_group_label>
    <arm_group_label>Udenafil Dose Level 2 qd</arm_group_label>
    <arm_group_label>Udenafil Dose Level 3 qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females with Fontan physiology who are 14-18 years of age.&#xD;
&#xD;
          2. Willingness to return to center to complete blood draws and exercise tests as&#xD;
             described in the study protocol.&#xD;
&#xD;
          3. Patients must agree to abstain from alcohol, caffeinated beverages, and grapefruit&#xD;
             juice for the duration of the trial.&#xD;
&#xD;
          4. Informed assent from subject informed consent from parent/legal guardian as&#xD;
             appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-cardiac medical, psychiatric, and/or social disorder that would prevent successful&#xD;
             completion of planned study testing or would invalidate its results.&#xD;
&#xD;
          2. Height &lt;132 cm (minimum height requirement for exercise stress testing).&#xD;
&#xD;
          3. Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary vein&#xD;
             stenosis resulting in a mean gradient of &gt;4 mmHg between the regions proximal and&#xD;
             distal to the obstruction.&#xD;
&#xD;
          4. Single lung physiology.&#xD;
&#xD;
          5. Severe ventricular dysfunction or valvular regurgitation (systemic atrioventricular or&#xD;
             semilunar valve) determined from review of the echocardiogram performed in closest&#xD;
             proximity to study enrollment.&#xD;
&#xD;
          6. Significant renal (serum creatinine &gt; 2.0), hepatic (serum aspartate aminotransferase&#xD;
             (AST) and/or alanine aminotransferase ( ALT) &gt; 3 times upper limit of normal),&#xD;
             gastrointestinal or biliary disorders that could impair absorption, metabolism or&#xD;
             excretion of orally administered medications, based on laboratory assessment at the&#xD;
             time of screening visit.&#xD;
&#xD;
          7. Hospitalization for acute decompensated heart failure within the 12 months preceding&#xD;
             study enrollment.&#xD;
&#xD;
          8. A diagnosis of active protein losing enteropathy or plastic bronchitis.&#xD;
&#xD;
          9. Active evaluation or listing for heart transplant.&#xD;
&#xD;
         10. History of use of a phosphodiesterase type 5 inhibitor within three months of study&#xD;
             enrollment.&#xD;
&#xD;
         11. Concurrent illness that, in the opinion of the investigator, precludes participation.&#xD;
&#xD;
         12. Current therapy with alpha-blockers or nitrates.&#xD;
&#xD;
         13. Pregnancy at the time of enrollment.&#xD;
&#xD;
         14. Latex allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Congenital Heart Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>July 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>Maximal Oxygen Consumption</keyword>
  <keyword>Vascular function</keyword>
  <keyword>EndoPAT</keyword>
  <keyword>Myocardial performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Univentricular Heart</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

